Ready-Made immune cells take on Hard-to-Treat cancers
NCT ID NCT06241456
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 study tests an experimental therapy called FT825, a type of immune cell that is made in a lab and can be given to any patient without needing to use their own cells. It is being tested in people with advanced solid tumors that have HER2 or other markers. The study will check safety and whether the cells can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FT825 (an off-the-shelf CAR T-cell therapy)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that are hard to treat.
What could go wrong
This is an early phase 1 trial focused on safety, so it is not yet known if FT825 will shrink tumors. Side effects from the therapy and chemotherapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Banner MD Anderson Cancer Center
RECRUITINGGilbert, Arizona, 85234, United States
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Ohio State University - Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
Oncology Hematology Care Clinial Trials
RECRUITINGCincinnati, Ohio, 45242, United States
-
Sarah Cannon Research Institute (SCRI) - Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
University of California San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92037, United States
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
-
University of Minnesota Medical School
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
-
Yale New Haven Hospital - Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States